| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Salicylate absorption follows first-order kinetics, with an absorption half-life of 5 to 16 minutes. Salicylate is typically excreted. Metabolism/Metabolites The metabolism of ethylene glycol salicylate is similar to that of other salicylates. The metabolic pathways of salicylate include: glucuronide formation (to salicylglucuronide and salicylphenol glucuronide), conjugation with glycine (to salicyluric acid), and oxidation to gentic acid. At low salicylate concentrations, the rates of salicylphenol glucuronide and salicyluric acid formation readily saturate, following Michaelis-Menten kinetics. Higher doses result in longer times required to reach steady-state salicylate concentrations. There is also evidence that enzymatic induction of salicyluric acid formation occurs during salicylate metabolism. Biological Half-Life The serum half-life of salicylate [DB00945] is 20 minutes. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
The plasma protein binding rate of salicylic acid depends on concentration and exhibits significant individual differences. |
| References | |
| Additional Infomation |
2-Hydroxyethyl Salicylate is a benzoic acid ester formed by the condensation of the carboxyl group of salicylic acid with a hydroxyl group of ethylene glycol. It belongs to the phenolic, primary alcohol, and salicylate class of compounds. Its function is related to ethylene glycol and salicylic acid. Ethylene glycol salicylate, also known as 2-hydroxyethyl salicylate, is a benzoic acid ester formed by the condensation of the carboxyl group of salicylic acid with a hydroxyl group of ethylene glycol. It is an active ingredient used in topical analgesic patches to relieve mild to moderate muscle and joint pain. This drug belongs to the salicylate class of drugs, which are used as analgesics to treat mild to moderate pain. Ethylene glycol salicylate (GS), composed of salicylic acid (SA) and ethylene glycol, is a nonsteroidal anti-inflammatory drug (NSAID). This ingredient is a key component in many topical creams and sprays used to relieve muscle, joint, and tendon pain, soreness, and stiffness.
Drug Indications This product is recommended only for the relief of muscle pain and rheumatic pain in humans and animals. Mechanism of Action Similar to other salicylates. Salicylates, along with other analgesics and anti-inflammatory drugs, particularly nonsteroidal anti-inflammatory drugs (NSAIDs) primarily used for rheumatic diseases, reduce prostaglandin synthesis by inhibiting cyclooxygenase. Pharmacodynamics Temporarily relieves mild to moderate pain. Works synergistically with ingredients that have a counterstimulatory effect, such as menthol. Topical analgesics relieve muscle or joint pain by stimulating or mildly inflamed skin, working by reducing inflammation in deeper, adjacent tissues. Analgesics relieve pain by interfering with the brain's reception of pain signals caused by conditions such as osteoarthritis (OA) or injuries such as sprains and strains. These drugs may cause vasodilation or skin irritation, producing a false feeling of heat or warmth. |
| Molecular Formula |
C9H10O4
|
|---|---|
| Molecular Weight |
182.1733
|
| Exact Mass |
182.057
|
| CAS # |
87-28-5
|
| PubChem CID |
6880
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
294.3±0.0 °C at 760 mmHg
|
| Melting Point |
25°C
|
| Flash Point |
128.3±15.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
1.16
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(O)=CC=CC=1)OCCO
|
| InChi Key |
LVYLCBNXHHHPSB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2
|
| Chemical Name |
2-hydroxyethyl 2-hydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~160 mg/mL (~878.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
